Cargando…
Zoledronate-pulsed dendritic cell-based anticancer vaccines
The addition of zoledronate to tumor-associated antigen (TAA)-loaded dendritic cells (DCs) promotes the activation of interferon γ-secreting Vγ9 γδ T cells, in turn eliciting TAA-specific CD8(+) T-cell responses. Immunological responses induced by zoledronate-pulsed DC-based vaccines have been assoc...
Autores principales: | Kamigaki, Takashi, Takahara, Masashi, Maekawa, Ryuji, Goto, Shigenori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850548/ https://www.ncbi.nlm.nih.gov/pubmed/24319636 http://dx.doi.org/10.4161/onci.25636 |
Ejemplares similares
-
Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial
por: Hirooka, Yoshiki, et al.
Publicado: (2017) -
Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013) -
A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy
por: McLellan, Alexander D
Publicado: (2014) -
Dendritic cell-based vaccines: Shining the spotlight on signal 3
por: Linette, Gerald P, et al.
Publicado: (2013) -
Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
por: Hailemichael, Yared, et al.
Publicado: (2013)